A Comprehensive Review of Movement Disorders for the Clinical Practitioner
**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support Acknowledgement</td>
<td>3</td>
</tr>
<tr>
<td>Course Faculty</td>
<td>4</td>
</tr>
<tr>
<td>CME &amp; Program Information</td>
<td>5</td>
</tr>
<tr>
<td>Course &amp; Live Session Lecture Listing</td>
<td>7</td>
</tr>
</tbody>
</table>

---

**Course Materials**

Registered participants can access recorded lectures for on demand viewing beginning July 20, 2020 via the link below:


The on-demand lectures are available now through August 15, 2020 to registered participants. Lectures are arranged by broadly by topic.

---

**International Parkinson and Movement Disorder Society**

**International Secretariat**

555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA  
Email: education@movementdisorders.org  
Tel: +1 (414) 276-2145 • Fax: +1 (414) 276-3349

The International Parkinson and Movement Disorder Society (MDS) is an international professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic Movement Disorders, and abnormalities in muscle tone and motor control.
COURSE SUPPORT ACKNOWLEDGEMENT

The *Virtual Comprehensive Review of Movement Disorders for the Clinical Practitioner* has received unrestricted medical education grants from the following:

- Acorda Therapeutics
- Allergan
- Merz North America
- Sanofi

The *Virtual Comprehensive Review of Movement Disorders for the Clinical Practitioner* is supported in part by educational grants from:

[Website Logo]

The *Virtual Comprehensive Review of Movement Disorders for the Clinical Practitioner* wishes to acknowledge the following commercial supporters and exhibitors:

- Adamas Pharmaceuticals Inc.
- Allergan
COURSE DIRECTORS

Michael S. Okun, MD  
University of Florida  
UF Health Center for Movement Disorders and Neurorestoration  
Gainesville, FL, United States

Cynthia Comella, MD, FAAN, FASM, FANA  
Rush University Medical Center  
Chicago, IL, United States

COURSE FACULTY

Stanley Fahn, MD  
Columbia University  
College of Physicians & Surgeons  
New York, NY, United States

Joseph Jankovic, MD, FAAN  
Baylor College of Medicine; Director, Parkinson’s Disease Center and Movement Disorders Clinic  
Houston, TX, United States

Jennifer G. Goldman, MD, MS, FAAN, FANA  
Northwestern University  
Feinberg School of Medicine  
Chicago, IL, United States

Mark Hallett, MD  
President, International Federation of Clinical Neurophysiology  
Bethesda, MD, United States

Kapil D. Sethi, MD, FRCP  
Augusta University  
Department of Neurology  
Augusta, GA, United States

VIDEO ROUNDS GUEST PANELISTS

Kailash Bhatia, MD, DM, FRCP  
University College London  
London, United Kingdom

Victor Fung, MBBS, PhD, FRACP  
University of Sydney  
Sydney, Australia

Marie Vidailhet, MD, PhD  
Salpetriere Hospital  
Paris, France
PROGRAM & CONTINUING MEDICAL EDUCATION (CME) INFORMATION

COURSE DESCRIPTION
This program will discuss the classification of Movement Disorders, their differential diagnosis, and their treatment. The course curriculum also covers the phenomenology, pathophysiology, pathogenesis, epidemiology, genetics, and other aspects of the entire field of Movement Disorders.

LEARNING OBJECTIVES
After participating in this activity, the learner will be able to:

- Recognize and classify parkinsonism, tremor, and other movement disorders
- Differentiate atypical parkinsonism from Parkinson's disease
- Appraise treatment approaches for parkinsonism, dystonia, tremor, chorea, and other movement disorders
- Evaluate the phenomenology and classification of functional (psychogenic) disorders
- Formulate and classify gait disorders in parkinsonism, ataxia, and other hypokinetic or hyperkinetic movement disorders

TARGET AUDIENCE
This course is designed for general neurologists, neurology residents, Movement Disorders fellows, and other health professionals.

OVERALL GOAL STATEMENT
The goal of this program is to provide information and practical information on various developments and standards within the field of Movement Disorders.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

TO CLAIM CREDIT
Participants of this educational program will have the opportunity to claim their CME credits using the Online Self-Report Form to print their CME certificate. CME Claim Site link will be provided beginning August 6, 2020.

Contact education@movementdisorders.org with questions on the CME Claim Site.

COURSE EVALUATIONS
Course evaluations are available online. A link will be provided to you upon conclusion of the course. Please take time to complete the online evaluation as your input and comments are essential in planning future educational programs.
CERTIFICATES OF ATTENDANCE
Certificates of attendance will be available through the Online Self Report Form for CME Claim.

CONTENT VALIDITY STATEMENT
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

RECORDINGS PROHIBITED
Audio and videotaping are not allowed during the course. Photography of the presentations and slides is not allowed during the activity. This includes mobile phone photography.

SATISFACTORY COMPLETION
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.

DISCLOSURE OF FINANCIAL RELATIONSHIPS
All individuals in control of content for this webinar are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME.

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Role in Activity</th>
<th>Disclosure(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cynthia</td>
<td>Comella</td>
<td>Planner, Speaker</td>
<td>Consultant: Merz Pharmaceuticals, Ipsen Pharmaceuticals, Revance Therapeutics, AEON Biopharma Intends to reference off-label/unapproved uses of drugs or devices</td>
</tr>
<tr>
<td>Stanley</td>
<td>Fahn</td>
<td>Speaker</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jennifer</td>
<td>Goldman</td>
<td>Speaker</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mark</td>
<td>Hallett</td>
<td>Speaker</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Joseph</td>
<td>Jankovic</td>
<td>Speaker</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Michael</td>
<td>Okun</td>
<td>Planner, Speaker</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kapil</td>
<td>Sethi</td>
<td>Speaker</td>
<td>Consultant: Merz, Sunovion, Neurocrine, Adamas, Pfizer, Cavion Grants: Kyowa, Lundbeck, US World Meds, Acorda, Biotie</td>
</tr>
<tr>
<td>Sanjay</td>
<td>Pandey</td>
<td>Reviewer</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Chandler</td>
<td>Gill</td>
<td>Reviewer</td>
<td>Nothing to Disclose</td>
</tr>
</tbody>
</table>
LECTURE LISTING AND Q&A SCHEDULE
All virtual Aspen Course lectures are grouped broadly by topic. Lectures and related slides are available for on demand viewing via the private course webpage. Please visit the virtual course site for the link to join the live session.

Parkinson’s Disease and Parkinsonism
*Join Us Live: Monday, August 3, 2020 at 12:30 US Central Time*

<table>
<thead>
<tr>
<th>Lecture Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview and Phenomenology of Movement Disorders: Part 1: Hypokinetic Disorders</td>
<td>Stanley Fahn</td>
</tr>
<tr>
<td>Motor Control</td>
<td>Mark Hallett</td>
</tr>
<tr>
<td>Environmental Causes and Pathologies of Parkinson’s Disease</td>
<td>Michael Okun</td>
</tr>
<tr>
<td>Etiopathogenesis of Parkinson’s Disease</td>
<td>Joseph Jankovic</td>
</tr>
<tr>
<td>Motor and Non-Motor Features of Parkinson’s Disease</td>
<td>Jennifer Goldman</td>
</tr>
<tr>
<td>Treatment of Non-Motor Symptoms of Parkinson’s Disease</td>
<td>Jennifer Goldman</td>
</tr>
<tr>
<td>Treatment of Motor Symptoms of Parkinson’s Disease</td>
<td>Cynthia Comella</td>
</tr>
<tr>
<td>Surgical Treatment of Parkinson Disease</td>
<td>Michael Okun</td>
</tr>
<tr>
<td>Atypical and Secondary Parkinsonism</td>
<td>Jennifer Goldman</td>
</tr>
</tbody>
</table>

Hyperkinetic Movement Disorders
*Join Us Live: Tuesday, August 4, 2020 at 09:00 US Central Time*

<table>
<thead>
<tr>
<th>Lecture Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview and Phenomenology of Movement Disorders: Part 2: Hyperkinetic Disorders</td>
<td>Stanley Fahn</td>
</tr>
<tr>
<td>Tremor &amp; Wilson’s Disease</td>
<td>Kapil Sethi</td>
</tr>
<tr>
<td>Dystonia: Phenomenology, Diagnosis, Genetics, Pathophysiology</td>
<td>Stanley Fahn</td>
</tr>
<tr>
<td>Treatment of Dystonia</td>
<td>Cynthia Comella</td>
</tr>
<tr>
<td>Chorea, Ballism, and Athetosis</td>
<td>Joseph Jankovic</td>
</tr>
<tr>
<td>Huntington's Disease</td>
<td>Jennifer Goldman</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>Mark Hallett</td>
</tr>
<tr>
<td>Tics and Tourette Syndrome</td>
<td>Joseph Jankovic</td>
</tr>
<tr>
<td>Tardive Syndromes and Drug Induced Movement Disorders</td>
<td>Cynthia Comella</td>
</tr>
<tr>
<td>Deep Brain Stimulation (DBS) in Hyperkinetic Disorders</td>
<td>Michael Okun</td>
</tr>
</tbody>
</table>
LECTURE LISTING AND Q&A SCHEDULE

Other Movement Disorders
Join Us Live: Wednesday, August 5, 2020 at 18:00 US Central Time

<table>
<thead>
<tr>
<th>Lecture Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal Ganglia: Anatomy &amp; Physiology</td>
<td>Mark Hallett</td>
</tr>
<tr>
<td>Autoimmune Movement Disorders</td>
<td>Joseph Jankovic</td>
</tr>
<tr>
<td>Ataxia</td>
<td>Mark Hallett</td>
</tr>
<tr>
<td>Restless Leg Syndrome and Peripheral Movement Disorders</td>
<td>Cynthia Comella</td>
</tr>
<tr>
<td>Psychogenic (Functional Movement Disorders)</td>
<td>Stanley Fahn</td>
</tr>
<tr>
<td>Paroxysmal Movement Disorders</td>
<td>Kapil Sethi</td>
</tr>
<tr>
<td>Gait Disorders</td>
<td>Mark Hallett</td>
</tr>
<tr>
<td>Movement Disorder Emergencies</td>
<td>Kapil Sethi</td>
</tr>
</tbody>
</table>

Supplementary Lecture

<table>
<thead>
<tr>
<th>Lecture Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Videos and Pearls for Approaching Deep Brain Stimulation</td>
<td>Michael Okun</td>
</tr>
</tbody>
</table>

The Virtual Aspen Course has an additional two sessions for interaction with the faculty. Please visit the virtual course for the link to join the live session.

Career Development and Mentorship
Join Us Live: Wednesday, August 5, 2020 at 12:00 US Central Time

<table>
<thead>
<tr>
<th>Supplementary Talk Title</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Career Development and Mentorship</td>
<td>Michael Okun</td>
</tr>
</tbody>
</table>

Video Rounds Session*
This session is not accredited to provide CME
Join Us Live: Thursday, August 6, 2020 at 12:00 US Central Time

Moderator: Dr. Kapil Sethi
The faculty would like to welcome the addition of guest panelists for the video rounds session.

<table>
<thead>
<tr>
<th>Guest Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kailash Bhatia  MD, DM, FRCP</td>
</tr>
<tr>
<td>University College London</td>
</tr>
<tr>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Victor Fung  MBBS, PhD, FRACP</td>
</tr>
<tr>
<td>University of Sydney</td>
</tr>
<tr>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>Marie Vidailhet, MD, PhD</td>
</tr>
<tr>
<td>Salpetriere Hospital</td>
</tr>
<tr>
<td>Paris, France</td>
</tr>
</tbody>
</table>
1.800.4PD.INFO
English/Español

What is the Parkinson’s Foundation Helpline?
The Helpline is a toll-free number for people with Parkinson’s disease, their families, friends and healthcare professionals to connect with a Parkinson’s disease information specialist and receive:

- Current information about Parkinson’s
- Referrals to healthcare professionals
- A wide variety of free publications
- Emotional Support
- Community Resources

When is the Helpline open?
The Helpline is open Monday through Friday from 9:00 a.m. to 8:00 p.m. ET. You can also email us at Helpline@Parkinson.org any time.

Who will I be talking to if I call?
Compassionate, trained Parkinson’s disease information specialists from various health professions.

Parkinson’s Foundation
Upholding an enduring commitment to move neuroscience forward

Our passion has always been—and will always be—finding new ways to help make a lasting impact on the lives of patients
41% DECREASE IN DYSKINESIA vs 14% with placebo\(^2\)
(UDysRS; primary endpoint)

36% DECREASE IN OFF TIME (1 hour) placebo-adjusted\(^2,3\)
(key secondary endpoint)

45% INCREASE IN "GOOD" ON TIME (3.8 hours) vs 17% with placebo\(^2,3\)
(1.4 hours)\(^2,3\)
(key secondary endpoint)

"Good" ON time = ON time without troublesome dyskinesia, UDysRS = Unified Dyskinesia Rating Scale.

GOCOVRI® is the first and only FDA-approved medication indicated for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications.\(^1\)

In clinical trials, GOCOVRI® reduced dyskinesia (UDysRS; primary endpoint) while also reducing OFF time (key secondary endpoint) through Week 12, leading to increased "good" ON time (ON time without troublesome dyskinesia; key secondary endpoint) throughout the day.\(^1\)

**INDICATION**

GOCOVRI® is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS**

GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m

**WARNINGS AND PRECAUTIONS**

**Falling Asleep During Activities of Daily Living and Somnolence:** Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

**Suicidality and Depression:** Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

**Hallucinations/Psychotic Behavior:** Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

**Dizziness and Orthostatic Hypotension:** Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

**Withdrawal-Emergent Hyperpyrexia and Confusion:** Rapid dose reduction or abrupt discontinuation of GOCOVRI may cause an increase in the symptoms of Parkinson's disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

**Impulse Control/Compulsive Behaviors:** Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

**ADVERSE REACTIONS**

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

Please see full Prescribing Information at www.GOCOVRI.com.

**REFERENCES**

SAVE THE DATE

International Parkinson and Movement Disorder Society

MDS Virtual Congress 2020

SEPTEMBER 12–SEPTEMBER 16

www.mdscongress.org